Drugs / (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00923390 | Mar 2009 → Aug 2012 | kidney cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923390 ↗ |
| Action | Deplete | “the new cells will attack and destroy the cancer cells” NCT00923390 ↗ |
| Route | Intravenous | “given back to the patient by intravenous (IV) transfusion” NCT00923390 ↗ |